SCHEMBL3769993

SCHEMBL3769993

CON(C)C(=O)c1cn2cc(C)ccc2n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 2/20 0.44
KDM4E B2RXH2 7/20 0.41
POLB P06746 2/20 0.41
RAB9A P51151 9/20 0.41
NPC1 O15118 8/20 0.41
SMN1; SMN2 Q16637 7/20 0.41
ALDH1A1 P00352 7/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
PAX8 Q06710 2/20 0.41
MITF O75030 1/20 0.41
KDM5A P29375 1/20 0.41
KDM5C P41229 1/20 0.41
HPGD P15428 5/20 0.40
MAPT P10636 3/20 0.40
EGLN1 Q9GZT9 2/20 0.40
LMNA P02545 1/20 0.40
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40
METTL3 Q86U44 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1500384 0.86 APP (0.47) APPKDM4EPOLBRAB9ANPC1
SCHEMBL2086662 0.86 HRH4 (0.52) APPKDM4EPOLBRAB9ANPC1
SCHEMBL15219328 0.84 APP (0.49) APPKDM4EPOLBRAB9ANPC1
SCHEMBL29870964 0.81 PTGS1 (0.59) KDM4EPOLBRAB9ANPC1SMN1; SMN2
SCHEMBL21246447 0.78 RAB9A (0.52) APPKDM4EPOLBRAB9ANPC1
SCHEMBL3659772 0.78 NR4A2 (0.59) EGLN1
SCHEMBL2638074 0.76 PTGS1 (0.59) APPKDM4EPOLBRAB9ANPC1
SCHEMBL16376280 0.76 RAB9A (0.50) APPKDM4EPOLBRAB9ANPC1
SCHEMBL2086824 0.75 GAA (0.36) KDM4ERAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL8065354 0.74 TGFBR1 (0.50) APPKDM4EPOLBRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317688-A1 2-HETEROAROYLIMIDAZOL[1,2-a]PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-12-16 US claimed
US-20100317688-A1 2-HETEROAROYLIMIDAZOL[1,2-a]PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317688-A1 2-HETEROAROYLIMIDAZOL[1,2-a]PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF XDH, CYP11B2, IL4I1 APP 3434/4885KDM4E 4134/4885POLB 2896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.